Drug-resistant tuberculosis: time for visionary political leadership

Hdl Handle:
http://hdl.handle.net/10144/295262
Title:
Drug-resistant tuberculosis: time for visionary political leadership
Authors:
Abubakar, Ibrahim; Zignol, Matteo; Falzon, Dennis; Raviglione, Mario; Ditiu, Lucica; Masham, Susan; Adetifa, Ifedayo; Ford, Nathan; Cox, Helen; Lawn, Stephen D; Marais, Ben J; McHugh, Timothy D; Mwaba, Peter; Bates, Matthew; Lipman, Marc; Zijenah, Lynn; Logan, Simon; McNerney, Ruth; Zumla, Adam; Sarda, Krishna; Nahid, Payam; Hoelscher, Michael; Pletschette, Michel; Memish, Ziad A; Kim, Peter; Hafner, Richard; Cole, Stewart; Migliori, Giovanni Battista; Maeurer, Markus; Schito, Marco; Zumla, Alimuddin
Journal:
The Lancet Infectious Diseases
Abstract:
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the epidemic; and suggest specific recommendations for important next steps. Visionary political leadership is needed to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of global and regional action plans.
Affiliation:
Centre for Infectious Disease Epidemiology, Department of Infection and Population Health, University College London, London, UK; Health Protection Agency, London, UK
Publisher:
Elsevier
Issue Date:
24-Mar-2013
URI:
http://hdl.handle.net/10144/295262
DOI:
10.1016/S1473-3099(13)70030-6
PubMed ID:
23531391
Submitted date:
2013-06-20
Language:
en
ISSN:
1474-4457
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorAbubakar, Ibrahimen_GB
dc.contributor.authorZignol, Matteoen_GB
dc.contributor.authorFalzon, Dennisen_GB
dc.contributor.authorRaviglione, Marioen_GB
dc.contributor.authorDitiu, Lucicaen_GB
dc.contributor.authorMasham, Susanen_GB
dc.contributor.authorAdetifa, Ifedayoen_GB
dc.contributor.authorFord, Nathanen_GB
dc.contributor.authorCox, Helenen_GB
dc.contributor.authorLawn, Stephen Den_GB
dc.contributor.authorMarais, Ben Jen_GB
dc.contributor.authorMcHugh, Timothy Den_GB
dc.contributor.authorMwaba, Peteren_GB
dc.contributor.authorBates, Matthewen_GB
dc.contributor.authorLipman, Marcen_GB
dc.contributor.authorZijenah, Lynnen_GB
dc.contributor.authorLogan, Simonen_GB
dc.contributor.authorMcNerney, Ruthen_GB
dc.contributor.authorZumla, Adamen_GB
dc.contributor.authorSarda, Krishnaen_GB
dc.contributor.authorNahid, Payamen_GB
dc.contributor.authorHoelscher, Michaelen_GB
dc.contributor.authorPletschette, Michelen_GB
dc.contributor.authorMemish, Ziad Aen_GB
dc.contributor.authorKim, Peteren_GB
dc.contributor.authorHafner, Richarden_GB
dc.contributor.authorCole, Stewarten_GB
dc.contributor.authorMigliori, Giovanni Battistaen_GB
dc.contributor.authorMaeurer, Markusen_GB
dc.contributor.authorSchito, Marcoen_GB
dc.contributor.authorZumla, Alimuddinen_GB
dc.date.accessioned2013-07-04T20:48:33Z-
dc.date.available2013-07-04T20:48:33Z-
dc.date.issued2013-03-24-
dc.date.submitted2013-06-20-
dc.identifier.citationDrug-resistant tuberculosis: time for visionary political leadership. 2013, 13 (6):529-39 Lancet Infect Disen_GB
dc.identifier.issn1474-4457-
dc.identifier.pmid23531391-
dc.identifier.doi10.1016/S1473-3099(13)70030-6-
dc.identifier.urihttp://hdl.handle.net/10144/295262-
dc.description.abstractTwo decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the epidemic; and suggest specific recommendations for important next steps. Visionary political leadership is needed to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of global and regional action plans.en_GB
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsPublished by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/journals/laninf[/url] for further relevant comment.en_GB
dc.subjectTuberculosisen_GB
dc.subjectHealth Policy/Access to Medicineen_GB
dc.titleDrug-resistant tuberculosis: time for visionary political leadershipen
dc.contributor.departmentCentre for Infectious Disease Epidemiology, Department of Infection and Population Health, University College London, London, UK; Health Protection Agency, London, UKen_GB
dc.identifier.journalThe Lancet Infectious Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.